Miguel Angel M.
- Country
- Spain
- Department
- Endocrinologia
Research Overview
- Phase III Randomized, Double‑Blind, Placebo‑Controlled Study of Elecoglipron in Adults with Obesity or Overweight, With or Without Type 2 Diabetes Mellitus
- Adjunctive Aticaprant and Antidepressant Therapy for Relapse Prevention in Major Depressive Disorder with Moderate-to-Severe Anhedonia: A Randomized, Double-Blind Study
Data & Insights
Has run more than one trial at 0 of 132 partner sites.
Specializations
Psychiatric Care
The investigator specializes in treating Major Depressive Disorder (MDD), with particular emphasis on patients experiencing moderate-to-severe anhedonia.
- Depression Management
- Anhedonia Treatment
- Mood Disorders
Their clinical interest focuses on innovative therapeutic approaches for treatment-resistant depression cases.
Treatment Strategies
The investigator explores adjunctive therapy approaches in psychiatric care, specifically combining antidepressant medications with novel therapeutic agents.
- Combination Therapy
- Relapse Prevention
- Long-term Treatment
Their work encompasses therapeutic strategies for maintaining stable response in depression treatment.
Therapeutic Focus
The investigator concentrates on SSRI/SNRI-based treatments and their optimization for patients with complex depressive disorders.
- Antidepressant Optimization
- Response Stabilization
- Symptom Management
Their expertise extends to evaluating therapeutic interventions for persistent depressive symptoms.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.